KRAS and cholangiocarcinoma: Oncogenic fusion events, which included BRAF-FAM129A (one patient with KRAS mutant disease) in mPDAC and FGFR2 (fusion partners WAC (one patient), PKD2L1 (one patient), TENC1 (one patient), and TBC1D4 (one patient)) in cholangiocarcinoma, were not uniquely contained in Cluster 1.